BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836-847. [PMID: 19194760 DOI: 10.1245/s10434-008-0295-2] [Cited by in Crossref: 326] [Cited by in F6Publishing: 301] [Article Influence: 25.1] [Reference Citation Analysis]
Number Citing Articles
1 D'Haese JG, Renz BW, Ilmer M, Werner J. [Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer]. Chirurg 2020;91:628-35. [PMID: 32424598 DOI: 10.1007/s00104-020-01190-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Fukahori M, Miwa K, Murotani K, Naito Y, Ushijima T, Sakaue T, Tanaka T, Nagasu S, Suga H, Kakuma T, Okabe Y, Torimura T. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Medicine (Baltimore) 2021;100:e26052. [PMID: 34011119 DOI: 10.1097/MD.0000000000026052] [Reference Citation Analysis]
3 Katz MH, Slack R, Bruno M, Mcmillan J, Fleming JB, Lee JE, Bednarski B, Papadopoulos J, Matin SF. Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of “TeleDischarge”. Journal of Surgical Research 2016;202:196-203. [DOI: 10.1016/j.jss.2015.12.054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
4 Bellizzi AM, Bloomston M, Zhou X, Iwenofu OH, Frankel WL. The mTOR Pathway is Frequently Activated in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Applied Immunohistochemistry & Molecular Morphology 2010;18:442-7. [DOI: 10.1097/pai.0b013e3181de115b] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
5 Qiu Y, Shimada K, Hiraoka N, Maeshiro K, Ching WK, Aoki-Kinoshita KF, Furuta K. Knowledge discovery for pancreatic cancer using inductive logic programming. IET Syst Biol 2014;8:162-8. [PMID: 25075529 DOI: 10.1049/iet-syb.2013.0044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hua J, Zhang B, Xu J, Liu J, Ni Q, He J, Zheng L, Yu X, Shi S. Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. Eur J Surg Oncol 2019;45:1069-76. [PMID: 30685327 DOI: 10.1016/j.ejso.2019.01.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
8 Kolbeinsson H, Hoppe A, Bayat A, Kogelschatz B, Mbanugo C, Chung M, Wolf A, Assifi MM, Wright GP. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery 2021;169:649-54. [PMID: 32807504 DOI: 10.1016/j.surg.2020.06.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhang LJ, Wang KB, Liu LS, Chen LZ, Peng BG, Liang LJ, Li Z, Xue L, Li W, Xia JT. Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma. BMC Cancer 2014;14:571. [PMID: 25104140 DOI: 10.1186/1471-2407-14-571] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
10 Weber GF, Kersting S, Haller F, Grützmann R. R1-Resektion beim Pankreaskarzinom. Chirurg 2017;88:764-70. [DOI: 10.1007/s00104-017-0462-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Pandé R, Roberts KJ. Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit? Front Oncol 2019;9:1060. [PMID: 31681596 DOI: 10.3389/fonc.2019.01060] [Reference Citation Analysis]
12 Nakano Y, Kitago M, Shinoda M, Abe Y, Yagi H, Hibi T, Takeuchi A, Aiura K, Itano O, Kitagawa Y. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med 2017;6:2278-86. [PMID: 28925039 DOI: 10.1002/cam4.1178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
13 Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797. [PMID: 26498594 DOI: 10.1186/s12885-015-1779-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 14.0] [Reference Citation Analysis]
14 Kim CB, Ahmed S, Hsueh EC. Current surgical management of pancreatic cancer. J Gastrointest Oncol 2011;2:126-35. [PMID: 22811842 DOI: 10.3978/j.issn.2078-6891.2011.029] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
15 Cooper AB, Holmes HM, des Bordes JK, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg 2014;219:111-20. [PMID: 24856952 DOI: 10.1016/j.jamcollsurg.2014.02.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
16 Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R, Ehrmann J, Melichar B, Yogeswara T, Klos D, Vrba R, Havlik R, Mohelnikova-Duchonova B. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature. World J Gastroenterol 2017; 23(35): 6420-6428 [PMID: 29085191 DOI: 10.3748/wjg.v23.i35.6420] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
17 Burmeister E, Waterhouse M, Jordan S, O'connell D, Merrett N, Goldstein D, Wyld D, Beesley V, Gooden H, Janda M, Neale R. Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. Pancreatology 2016;16:873-81. [DOI: 10.1016/j.pan.2016.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Barugola G, Partelli S, Crippa S, Capelli P, D’Onofrio M, Pederzoli P, Falconi M. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203:132-139. [PMID: 21824596 DOI: 10.1016/j.amjsurg.2011.03.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
19 Colloca GA, Venturino A, Guarneri D. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy. Clin Exp Metastasis 2019;36:519-25. [PMID: 31578654 DOI: 10.1007/s10585-019-09996-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, Varadhachary GR, Abbruzzese JL, Wolff RA, Ahmad SA. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013;20:2197-2203. [PMID: 23408126 DOI: 10.1245/s10434-013-2889-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
21 Tamm EP, Balachandran A, Bhosale PR, Katz MH, Fleming JB, Lee JH, Varadhachary GR. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am. 2012;50:407-428. [PMID: 22560689 DOI: 10.1016/j.rcl.2012.03.008] [Cited by in Crossref: 102] [Cited by in F6Publishing: 83] [Article Influence: 10.2] [Reference Citation Analysis]
22 Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 2012;215:41-51; discussion 51-2. [PMID: 22608401 DOI: 10.1016/j.jamcollsurg.2012.03.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
23 Hou X, Li Q, Yang L, Yang Z, He J, Li Q, Li D. KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer. Exp Biol Med (Maywood) 2021;246:1869-83. [PMID: 34171978 DOI: 10.1177/15353702211023473] [Reference Citation Analysis]
24 Li X, Yang L, Yuan Z, Lou J, Fan Y, Shi A, Huang J, Zhao M, Wu Y. Multi-institutional development and external validation of machine learning-based models to predict relapse risk of pancreatic ductal adenocarcinoma after radical resection. J Transl Med 2021;19:281. [PMID: 34193166 DOI: 10.1186/s12967-021-02955-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Pilgrim CH, Tsai S, Evans DB, Christians KK. Mesocaval Shunting: A Novel Technique to Facilitate Venous Resection and Reconstruction and Enhance Exposure of the Superior Mesenteric and Celiac Arteries during Pancreaticoduodenectomy. Journal of the American College of Surgeons 2013;217:e17-20. [DOI: 10.1016/j.jamcollsurg.2013.05.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
26 Katz MHG, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PWT, Lee JE, Vauthey J, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-laly X, Charnsangavej C, Fleming JB. Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. J Gastrointest Surg 2012;16:68-79. [DOI: 10.1007/s11605-011-1748-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
27 Low TY, Koh YX, Teo JY, Goh BKP. Short-Term Outcomes of Extended Pancreatectomy: A Single-Surgeon Experience. Gastrointest Tumors 2018;4:72-83. [PMID: 29594108 DOI: 10.1159/000484523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, Kozarek RA. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Ann Surg Oncol 2017;24:1722-30. [PMID: 28054192 DOI: 10.1245/s10434-016-5716-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
29 Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther 2016;9:7459-67. [PMID: 28003762 DOI: 10.2147/OTT.S100510] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
30 Chen SC, Shyr YM, Wang SE. Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. HPB (Oxford). 2013;15:951-957. [PMID: 23472708 DOI: 10.1111/hpb.12071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
31 Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Am J Surg Pathol 2016;40:1653-60. [PMID: 27631521 DOI: 10.1097/PAS.0000000000000738] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 11.2] [Reference Citation Analysis]
32 Ye S, Bai L. Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. Cancer Manag Res 2018;10:3405-17. [PMID: 30237742 DOI: 10.2147/CMAR.S173444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Kim MJ, Lee KH, Lee KT, Lee JK, Ku BH, Oh CR, Heo JS, Choi SH, Choi DW. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer. Pancreas. 2012;41:897-903. [PMID: 22699202 DOI: 10.1097/mpa.0b013e318252f4f5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 2.1] [Reference Citation Analysis]
34 Morifuji Y, Onishi H, Iwasaki H, Imaizumi A, Nakano K, Tanaka M, Katano M. Reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic cancer through the Hedgehog signaling. Cancer Sci. 2014;105:324-333. [PMID: 24397700 DOI: 10.1111/cas.12348] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
35 Li Q, Zhang L, Li X, Yan H, Yang L, Li Y, Li T, Wang J, Cao B. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer. BMC Cancer 2016;16:910. [PMID: 27871278 DOI: 10.1186/s12885-016-2889-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
36 Serafini S, Sperti C, Friziero A, Brazzale AR, Buratin A, Ponzoni A, Moletta L. Systematic Review and Meta-Analysis of Surgical Treatment for Isolated Local Recurrence of Pancreatic Cancer. Cancers (Basel) 2021;13:1277. [PMID: 33805716 DOI: 10.3390/cancers13061277] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Luu AM, Belyaev O, Höhn P, Praktiknjo M, Janot M, Uhl W, Braumann C. Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. J Gastrointest Oncol 2021;12:474-83. [PMID: 34012641 DOI: 10.21037/jgo-20-433] [Reference Citation Analysis]
39 Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Nomoto S. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. 2014;44:1692-1701. [PMID: 24114022 DOI: 10.1007/s00595-013-0752-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
40 Wong SK, Gondara L, Renouf DJ, Lim HJ, Loree JM, Davies JM, Gill S. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. J Gastrointest Oncol 2021;12:446-54. [PMID: 34012638 DOI: 10.21037/jgo-20-422] [Reference Citation Analysis]
41 Pine JK, Haugk B, Robinson SM, Darne A, Wilson C, Sen G, French JJ, White SA, Manas DM, Charnley RM. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions. Pancreatology 2020;20:537-44. [PMID: 31996296 DOI: 10.1016/j.pan.2020.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
42 Ven Fong Z, Chang DC, Lillemoe KD, Nipp RD, Tanabe KK, Qadan M. Contemporary Opportunity for Prehabilitation as Part of an Enhanced Recovery after Surgery Pathway in Colorectal Surgery. Clin Colon Rectal Surg 2019;32:95-101. [PMID: 30833857 DOI: 10.1055/s-0038-1676473] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Kim HW, Lee JC, Paik KH, Lee YS, Hwang JH, Kim J. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Medicine (Baltimore) 2015;94:e1012. [PMID: 26107667 DOI: 10.1097/MD.0000000000001012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
44 Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study. Acta Oncologica 2016;55:265-77. [DOI: 10.3109/0284186x.2015.1068445] [Cited by in Crossref: 67] [Cited by in F6Publishing: 32] [Article Influence: 9.6] [Reference Citation Analysis]
45 Zheng J, Huang S, Huang Y, Song L, Yin Y, Kong W, Chen X, Ouyang X. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma. Tumour Biol 2016;37:7853-9. [PMID: 26695153 DOI: 10.1007/s13277-015-4675-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
46 Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Surgery 2019;165:751-9. [PMID: 30551868 DOI: 10.1016/j.surg.2018.10.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
47 Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol 2017;116:25-34. [PMID: 28591939 DOI: 10.1002/jso.24623] [Cited by in Crossref: 41] [Cited by in F6Publishing: 53] [Article Influence: 8.2] [Reference Citation Analysis]
48 Huang H, Zou Y, Zhang H, Li X, Li Y, Deng X, Sun H, Guo Z, Ao L. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma. Transl Res 2020;219:30-44. [PMID: 32119844 DOI: 10.1016/j.trsl.2020.02.004] [Reference Citation Analysis]
49 Schiffman SC, Abberbock S, Winters S, Valko C, Steve J, Zureikat AH, Zeh HJ, Hogg ME. A pancreatic cancer multidisciplinary clinic: insights and outcomes. Journal of Surgical Research 2016;202:246-52. [DOI: 10.1016/j.jss.2016.01.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
50 Beermann S, Chakkalakal D, Muckelbauer R, Weißbach L, Holmberg C. "We talk it over"--mixed-method study of interdisciplinary collaborations in private practice among urologists and oncologists in Germany. BMC Cancer 2014;14:746. [PMID: 25282479 DOI: 10.1186/1471-2407-14-746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
51 Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012;122:639-53. [PMID: 22232209 DOI: 10.1172/JCI59227] [Cited by in Crossref: 421] [Cited by in F6Publishing: 292] [Article Influence: 42.1] [Reference Citation Analysis]
52 Wu L, Zhu L, Xu K, Zhou S, Zhou Y, Zhang T, Hang J, Zee BC. Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data. J Cancer 2021;12:1715-21. [PMID: 33613759 DOI: 10.7150/jca.50317] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersen GM, Tang AH. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. Br J Cancer 2015;112:514-22. [PMID: 25584484 DOI: 10.1038/bjc.2014.659] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
54 Riall TS, Brown KM. Individualizing care for locoregional pancreatic cancer? J Surg Res 2013;179:41-4. [PMID: 22221606 DOI: 10.1016/j.jss.2011.10.041] [Reference Citation Analysis]
55 Petzel MQ, Parker NH, Valentine AD, Simard S, Nogueras-Gonzalez GM, Lee JE, Pisters PW, Vauthey JN, Fleming JB, Katz MH. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol 2012;19:4078-84. [PMID: 22875648 DOI: 10.1245/s10434-012-2566-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
56 Farrell JJ. Intraductal papillary mucinous neoplasm to pancreas ductal adenocarcinoma sequence and pancreas cancer screening. Endosc Ultrasound 2018;7:314-8. [PMID: 30323160 DOI: 10.4103/eus.eus_49_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Karachristos A, Esnaola NF. Surgical management of pancreatic neoplasms: what’s new? Curr Gastroenterol Rep. 2014;16:397. [PMID: 25064316 DOI: 10.1007/s11894-014-0397-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
58 Fujii Y, Kamachi H, Matsuzawa F, Mizukami T, Kobayashi N, Fukai M, Taketomi A. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model. Invest New Drugs 2021. [PMID: 33905019 DOI: 10.1007/s10637-021-01118-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
60 Liles JS, Katz MH. Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma. Expert Rev Anticancer Ther. 2014;14:919-929. [PMID: 24833085 DOI: 10.1586/14737140.2014.919860] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
61 Lee JH, Kang CM, Bang SM, Choi JY, Seong JS, Hwang HK, Choi SH, Lee WJ. The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement. Medicine (Baltimore) 2015;94:e1233. [PMID: 26252282 DOI: 10.1097/MD.0000000000001233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
62 Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014;43:183-189. [PMID: 24518495 DOI: 10.1097/mpa.0000000000000088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
63 Sabater L, Muñoz E, Roselló S, Dorcaratto D, Garcés-Albir M, Huerta M, Roda D, Gómez-Mateo MC, Ferrández-Izquierdo A, Darder A, Cervantes A. Borderline resectable pancreatic cancer. Challenges and controversies. Cancer Treat Rev 2018;68:124-35. [PMID: 29957372 DOI: 10.1016/j.ctrv.2018.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
64 Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014;3:406-415. [PMID: 24519894 DOI: 10.1002/cam4.204] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 9.3] [Reference Citation Analysis]
65 Qiao P, Ayat NR, Vaidya A, Gao S, Sun W, Chou S, Han Z, Gilmore H, Winter JM, Lu ZR. Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts. Front Oncol 2020;10:586727. [PMID: 33194740 DOI: 10.3389/fonc.2020.586727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Okui M, Yamamichi T, Asakawa A, Harada M, Horio H. Resection for Pancreatic Cancer Lung Metastases. Korean J Thorac Cardiovasc Surg 2017;50:326-8. [PMID: 29124023 DOI: 10.5090/kjtcs.2017.50.5.326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
67 Suman P, Rutledge J, Yiengpruksawan A. Robotic distal pancreatectomy. JSLS 2013;17:627-35. [PMID: 24398207 DOI: 10.4293/108680813X13794522667409] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
68 Kurreck A, Weckwerth J, Modest DP, Striefler JK, Bahra M, Bischoff S, Pelzer U, Oettle H, Kruger S, Riess H, Sinn M. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. Eur J Cancer 2021;150:250-9. [PMID: 33940349 DOI: 10.1016/j.ejca.2021.03.036] [Reference Citation Analysis]
69 Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther. 2010;9:2068-2078. [PMID: 20606044 DOI: 10.1158/1535-7163.mct-10-0201] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
70 Hashimoto D, Chikamoto A, Ohmuraya M, Abe S, Nakagawa S, Beppu T, Takamori H, Hirota M, Baba H. Impact of Postoperative Weight Loss on Survival After Resection for Pancreatic Cancer. JPEN J Parenter Enteral Nutr. 2015;39:598-603. [PMID: 24486859 DOI: 10.1177/0148607114520992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
71 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362-375. [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060.computational] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Mehtsun WT, Hashimoto DA, Ferrone CR. Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. Advances in Surgery 2019;53:253-69. [DOI: 10.1016/j.yasu.2019.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27:358-367. [PMID: 26361405 DOI: 10.3978/j.issn.1000-9604.2015.05.02] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
74 Katz MH, Hu CY, Fleming JB, Pisters PW, Lee JE, Chang GJ. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg 2012;147:513-9. [PMID: 22351874 DOI: 10.1001/archsurg.2011.2281] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
75 Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, De Vita F, Petrillo A. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Front Oncol 2021;11:695627. [PMID: 34485130 DOI: 10.3389/fonc.2021.695627] [Reference Citation Analysis]
76 Thomas RM, Truty MJ, Kim M, Kang Y, Zhang R, Chatterjee D, Katz MH, Fleming JB. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2015;22:1884-92. [PMID: 25404477 DOI: 10.1245/s10434-014-4241-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
77 Peng JS, Wey J, Chalikonda S, Allende DS, Walsh RM, Morris-stiff G. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. Hepatobiliary & Pancreatic Diseases International 2019;18:373-8. [DOI: 10.1016/j.hbpd.2019.05.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
78 Barreto SG. Pancreatic cancer in Australia: is not it time we address the inequitable resource problem? Future Oncol 2020;16:1385-92. [PMID: 32412798 DOI: 10.2217/fon-2020-0109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
79 Hlavac V, Mohelnikova-Duchonova B, Lovecek M, Ehrmann J, Brynychova V, Kolarova K, Soucek P. Targeted Sequencing of Pancreatic Adenocarcinomas from Patients with Metachronous Pulmonary Metastases. Genes (Basel) 2020;11:E1391. [PMID: 33255265 DOI: 10.3390/genes11121391] [Reference Citation Analysis]
80 Laheru D, Biedrzycki B, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods Mol Biol. 2013;980:175-203. [PMID: 23359154 DOI: 10.1007/978-1-62703-287-2_9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
81 Cusworth BM, Krasnick BA, Nywening TM, Woolsey CA, Fields RC, Doyle MM, Liu J, Hawkins WG. Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 2017;19:147-53. [PMID: 27939807 DOI: 10.1016/j.hpb.2016.10.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
82 Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MPW, van Santvoort HC, Molenaar IQ. The diagnostic performance of CT vs FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.Eur J Radiol. 2018;106:128-136. [PMID: 30150034 DOI: 10.1016/j.ejrad.2018.07.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
83 Fabregat J, Busquets J, Peláez N, Jorba R, García-borobia F, Masuet C, Valls C, Ruiz-osuna S, Serrano T, Galán M, Cambray M, Laquente B, Ramos E, Rafecas A. Tratamiento quirúrgico del adenocarcinoma pancreático mediante duodenopancreatectomía cefálica (parte 2). Seguimiento a largo plazo tras 204 casos. Cirugía Española 2010;88:374-82. [DOI: 10.1016/j.ciresp.2010.09.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
84 Robinson SM, Rahman A, Haugk B, French JJ, Manas DM, Jaques BC, Charnley RM, White SA. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2012;38:333-339. [PMID: 22317758 DOI: 10.1016/j.ejso.2011.12.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
85 Kim DW, Lee SS, Kim SO, Kim JH, Kim HJ, Byun JH, Yoo C, Kim KP, Song KB, Kim SC. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score. Radiology 2020;296:541-51. [PMID: 32662759 DOI: 10.1148/radiol.2020200281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
86 Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, Marek T, Nasierowska-Guttmejer A, Nowakowska-Duława E, Rydzewska G, Strzelczyk J, Śledziński Z, Małecka-Panas E. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol 2019;14:1-18. [PMID: 30944673 DOI: 10.5114/pg.2019.83422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
87 Hoffe S, Rao N, Shridhar R. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Semin Radiat Oncol 2014;24:113-25. [PMID: 24635868 DOI: 10.1016/j.semradonc.2013.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
88 Bellizzi AM, Frankel WL. Pancreatic Pathology: A Practical Review. Lab Med 2009;40:417-26. [DOI: 10.1309/lm5my3ocdwwks6nm] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
89 Zhang Y, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M, Pasca di Magliano M. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013;73:4909-4922. [PMID: 23761328 DOI: 10.1158/0008-5472.can-12-4384] [Cited by in Crossref: 121] [Cited by in F6Publishing: 84] [Article Influence: 13.4] [Reference Citation Analysis]
90 Sakaguchi T, Valente R, Tanaka K, Satoi S, Del Chiaro M. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. Pancreatology 2019;19:672-80. [PMID: 31285145 DOI: 10.1016/j.pan.2019.05.466] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
91 Allen CJ, Thaker NG, Prakash L, Kruse BC, Feeley TW, Kaplan RS, Huey R, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. Ann Surg 2021;273:e7-9. [PMID: 32568750 DOI: 10.1097/SLA.0000000000004050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Dutta SK, Girotra M, Singla M, Dutta A, Otis Stephen F, Nair PP, Merchant NB. Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas 2012;41:530-4. [PMID: 22158074 DOI: 10.1097/MPA.0b013e3182374ace] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
93 Pointer DT Jr, Roife D, Powers BD, Murimwa G, Elessawy S, Thompson ZJ, Schell MJ, Hodul PJ, Pimiento JM, Fleming JB, Malafa MP. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. BMC Cancer 2020;20:750. [PMID: 32782024 DOI: 10.1186/s12885-020-07182-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
94 Shimizu T, Taniguchi K, Asakuma M, Komeda K, Inoue Y, Lee SW, Hirokawa F, Uchiyama K. Initial pulmonary metastasis after pancreatectomy for pancreatic ductal adenocarcinoma. Surg Today 2020;50:413-8. [PMID: 31673783 DOI: 10.1007/s00595-019-01902-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N. Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg. 2010;34:1908-1915. [PMID: 20376443 DOI: 10.1007/s00268-010-0570-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
96 Shima Y, Okabayashi T, Kozuki A, Sumiyoshi T, Tokumaru T, Saisaka Y, Date K, Iwata J. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. Langenbecks Arch Surg 2015;400:973-8. [DOI: 10.1007/s00423-015-1355-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
97 Lavu H, Mascaro AA, Grenda DR, Sauter PK, Leiby BE, Croker SP, Witkiewicz A, Berger AC, Rosato EL, Kennedy EP, Yeo CJ. Margin Positive Pancreaticoduodenectomy Is Superior to Palliative Bypass in Locally Advanced Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 2009;13:1937-47. [DOI: 10.1007/s11605-009-1000-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
98 Wang L, Wang Y, Li PP, Wang R, Zhu Y, Zheng F, Li L, Cui JJ, Wang LW. Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma. Tumour Biol 2016. [PMID: 27747589 DOI: 10.1007/s13277-016-5457-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
99 LaRocca CJ, Warner SG. A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer. Biomedicines 2018;6:E104. [PMID: 30400571 DOI: 10.3390/biomedicines6040104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
100 Vassaux G, Angelova A, Baril P, Midoux P, Rommelaere J, Cordelier P. The Promise of Gene Therapy for Pancreatic Cancer. Hum Gene Ther 2016;27:127-33. [PMID: 26603492 DOI: 10.1089/hum.2015.141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
101 Morimoto D, Yamada S, Sonohara F, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Pancreas 2020;49:699-705. [PMID: 32433409 DOI: 10.1097/MPA.0000000000001559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Satoi S, Yanagimoto H, Toyokawa H, Yamamoto T, Hirooka S, Yui R, Yamaki S, Matsui Y, Kitade H, Tanigawa N, Takai S, Kwon A. Long-Term Results of Surgical Resection After Preoperative Chemoradiation in Patients With Pancreatic Cancer. Pancreas 2012;41:333-5. [DOI: 10.1097/mpa.0b013e318229758f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
103 Watanabe Y, Nishihara K, Matsumoto S, Okayama T, Abe Y, Nakano T. Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review. Surg Today 2017;47:555-67. [DOI: 10.1007/s00595-016-1426-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
104 Attiyeh MA, Amini A, Chung V, Melstrom LG. Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. J Surg Oncol 2021;123:1395-404. [PMID: 33831247 DOI: 10.1002/jso.26415] [Reference Citation Analysis]
105 Cooperman AM, Bruckner H, Snady H, Hammerman H, Fader A, Feld M, Golier F, Rush T, Siegal J, Kasmin F, Cohen S, Wayne MG, Iskandar ME, Steele JG. Cancer of the Pancreas-Actual 5, 10, and 20+Year Survival: The Lucky and Fortunate Few. Surg Clin North Am. 2018;98:73-85. [PMID: 29191279 DOI: 10.1016/j.suc.2017.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
106 Jäger R, Weigel R, Forthuber B, Ganswindt U. Integrating radiation oncology into the management of pancreatic cancer. Eur Surg 2019;51:139-45. [DOI: 10.1007/s10353-019-0577-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Ottenhof NA, Morsink FH, Ten Kate F, van Noorden CJ, Offerhaus GJ. Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr) 2012;35:119-26. [PMID: 22351431 DOI: 10.1007/s13402-012-0072-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
108 Anderson KL Jr, Adam MA, Thomas S, Roman SA, Sosa JA. Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. Am J Surg 2017;213:601-5. [PMID: 28093119 DOI: 10.1016/j.amjsurg.2017.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
109 Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW; American College of Surgeons Oncology Group. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011;18:337-344. [PMID: 20811779 DOI: 10.1245/s10434-010-1282-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
110 Turrini O, Waters JA, Schnelldorfer T, Lillemoe KD, Yiannoutsos CT, Farnell MB, Sarr MG, Schmidt CM. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford) 2010;12:447-55. [PMID: 20815853 DOI: 10.1111/j.1477-2574.2010.00196.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
111 Matsuki R, Sugiyama M, Takei H, Kondo H, Fujiwara M, Shibahara J, Furuse J. Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. Surg Case Rep 2018;4:26. [PMID: 29589221 DOI: 10.1186/s40792-018-0435-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
112 Fisher AV, Ma Y, Wang X, Campbell-flohr SA, Rathouz PJ, Ronnekleiv-kelly SM, Abbott DE, Weber SM. National Trends in Centralization of Surgical Care and Multimodality Therapy for Pancreatic Adenocarcinoma. J Gastrointest Surg 2020;24:2021-9. [DOI: 10.1007/s11605-019-04361-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, Merchant N, Johnson CS, Lillemoe KD, Grützmann R. Pancreatic Acinar Cell Carcinoma: A Multi-institutional Study. J Gastrointest Surg 2009;13:1495-502. [DOI: 10.1007/s11605-009-0938-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
114 Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, Varadhachary G, Wolff RA, Katz MH. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 2012;14:365-72. [PMID: 22568412 DOI: 10.1111/j.1477-2574.2012.00445.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
115 Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD, di Magliano MP. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 2013;73:6359-74. [PMID: 24097820 DOI: 10.1158/0008-5472.CAN-13-1558-T] [Cited by in Crossref: 133] [Cited by in F6Publishing: 90] [Article Influence: 14.8] [Reference Citation Analysis]
116 Li GJ, Xu HW, Ji JJ, Yang F, Gao BQ. Prognostic value of preoperative lymphocyte-to-monocyte ratio in pancreatic adenocarcinoma. Onco Targets Ther 2016;9:1085-92. [PMID: 27042101 DOI: 10.2147/OTT.S96707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
117 Fonseca AL, Fleming JB. Surgery for pancreatic cancer: critical radiologic findings for clinical decision making. Abdom Radiol 2018;43:374-82. [DOI: 10.1007/s00261-017-1332-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
118 Dale W, Hemmerich J, Kamm A, Posner MC, Matthews JB, Rothman R, Palakodeti A, Roggin KK. Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014;259:960-965. [PMID: 24096757 DOI: 10.1097/sla.0000000000000226] [Cited by in Crossref: 85] [Cited by in F6Publishing: 41] [Article Influence: 10.6] [Reference Citation Analysis]
119 Kenkel JA, Tseng WW, Davidson MG, Tolentino LL, Choi O, Bhattacharya N, Seeley ES, Winer DA, Reticker-Flynn NE, Engleman EG. An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. Cancer Res 2017;77:4158-70. [PMID: 28611041 DOI: 10.1158/0008-5472.CAN-16-2212] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
120 Takeda Y, Saiura A, Takahashi Y, Inoue Y, Ishizawa T, Mise Y, Matsumura M, Ichida H, Matsuki R, Tanaka M, Ito H. Asymptomatic Pancreatic Cancer: Does Incidental Detection Impact Long-Term Outcomes? J Gastrointest Surg 2017;21:1287-95. [DOI: 10.1007/s11605-017-3421-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
121 Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794-1801. [PMID: 20162463 DOI: 10.1245/s10434-010-0943-1] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 8.2] [Reference Citation Analysis]
122 Russ AJ, Weber SM, Rettammel RJ, Mahvi DM, Rikkers LF, Cho CS. Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. Ann Surg Oncol. 2010;17:371-376. [PMID: 19851808 DOI: 10.1245/s10434-009-0759-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
123 Roth MT, Berlin JD. Current Concepts in the Treatment of Resectable Pancreatic Cancer. Curr Oncol Rep 2018;20. [DOI: 10.1007/s11912-018-0685-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
124 Nienhuijs SW, Rutten HJ, Luiten EJ, van Driel OJ, Reemst PH, Lemmens VE, de Hingh IH. Reduction of in-hospital mortality following regionalisation of pancreatic surgery in the south-east of the Netherlands. Eur J Surg Oncol 2010;36:652-6. [PMID: 20537840 DOI: 10.1016/j.ejso.2010.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
125 Busquets J, Fabregat J, Verdaguer H, Laquente B, Pelaez N, Secanella L, Leiva D, Serrano T, Cambray M, Lopez-Urdiales R, Ramos E. Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma. Cir Esp 2017;95:447-56. [PMID: 28992935 DOI: 10.1016/j.ciresp.2017.07.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Gundara JS, Wang F, Alvarado-Bachmann R, Williams N, Choi J, Gananadha S, Gill AJ, Hugh TJ, Samra JS. The clinical impact of early complete pancreatic head devascularisation during pancreatoduodenectomy. Am J Surg 2013;206:518-25. [PMID: 23809671 DOI: 10.1016/j.amjsurg.2013.01.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
127 Deobald RG, Cheng ES, Ko YJ, Wright FC, Karanicolas PJ. A qualitative study of patient and clinician attitudes regarding surveillance after a resection of pancreatic and peri-ampullary cancer. HPB (Oxford) 2015;17:409-15. [PMID: 25545219 DOI: 10.1111/hpb.12378] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
128 Baimas-George M, Watson M, Thompson K, Shastry V, Iannitti D, Martinie JB, Baker E, Parala-Metz A, Vrochides D. Prehabilitation for Hepatopancreatobiliary Surgical Patients: Interim Analysis Demonstrates a Protective Effect From Neoadjuvant Chemotherapy and Improvement in the Frailty Phenotype. Am Surg 2021;87:714-24. [PMID: 33170023 DOI: 10.1177/0003134820952378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Link JM, Liudahl SM, Betts CB, Sivagnanam S, Leis KR, McDonnell M, Pelz CR, Johnson B, Hamman KJ, Keith D, Sampson JE, Morgan TK, Lopez CD, Coussens LM, Sears RC. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. JCO Precis Oncol 2021;5:PO. [PMID: 34036232 DOI: 10.1200/PO.20.00287] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Takahashi H, Ohigashi H, Ishikawa O, Gotoh K, Yamada T, Nagata S, Tomita Y, Eguchi H, Doki Y, Yano M. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255:95-102. [PMID: 22123160 DOI: 10.1097/sla.0b013e31823d813c] [Cited by in Crossref: 79] [Cited by in F6Publishing: 28] [Article Influence: 7.9] [Reference Citation Analysis]
131 Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T. Comparative Outcomes Between Initially Unresectable and Recurrent Cases of Advanced Pancreatic Cancer Following Palliative Chemotherapy. Pancreas 2014;43:411-6. [DOI: 10.1097/mpa.0000000000000050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
132 Ouaissi M, Hubert C, Verhelst R, Astarci P, Sempoux C, Jouret-Mourin A, Loundou A, Gigot JF; Multidisciplary HPB Group of Center of Cancer. Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure. World J Surg. 2010;34:2648-2661. [PMID: 20607257 DOI: 10.1007/s00268-010-0699-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
133 Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012;36:409-417. [PMID: 22301497 DOI: 10.1097/pas.0b013e31824104c5] [Cited by in Crossref: 94] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
134 Nakagawa K, Akahori T, Nishiwada S, Nagai M, Nakamura K, Tanaka T, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Ikeda N, Sho M. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 2018;403:693-700. [PMID: 30218193 DOI: 10.1007/s00423-018-1709-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
135 Mierke F, Hempel S, Distler M, Aust DE, Saeger HD, Weitz J, Welsch T. Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection. Ann Surg Oncol. 2016;23:730-736. [PMID: 27554501 DOI: 10.1245/s10434-016-5515-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
136 Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
137 Furtado FS, Ferrone CR, Lee SI, Vangel M, Rosman DA, Weekes C, Qadan M, Fernandez-Del Castillo C, Ryan DP, Blaszkowsky LS, Hong TS, Clark JW, Striar R, Groshar D, Cañamaque LG, Umutlu L, Catalano OA. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol 2021;23:456-66. [PMID: 33415677 DOI: 10.1007/s11307-020-01569-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696-1704. [PMID: 22644446 DOI: 10.1007/s11605-012-1912-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 7.2] [Reference Citation Analysis]
139 Hackert T, Ulrich A, Büchler MW. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? Adv Surg 2017;51:1-10. [PMID: 28797331 DOI: 10.1016/j.yasu.2017.03.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
140 Allen CJ, Eska JS, Thaker NG, Feeley TW, Kaplan RS, Huey RW, Tzeng CD, Lee JE, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. J Surg Res 2021;262:115-20. [PMID: 33561722 DOI: 10.1016/j.jss.2020.12.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Kaissis GA, Lohöfer FK, Ziegelmayer S, Danner J, Jäger C, Schirren R, Ankerst D, Ceyhan GO, Friess H, Rummeny EJ, Weichert W, Braren RF. Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration. PLoS One 2019;14:e0208717. [PMID: 30601813 DOI: 10.1371/journal.pone.0208717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
142 Milella M, Bassi C, Boggi U, Brunetti O, Cavaliere A, Crippa S, De Vita F, Falconi M, Frassineti GL, Giommoni E, Macchini M, Malleo G, Silvestris N, Tudisco A, Vasile E, Reni M. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Crit Rev Oncol Hematol 2021;169:103571. [PMID: 34923121 DOI: 10.1016/j.critrevonc.2021.103571] [Reference Citation Analysis]
143 Lovecek M, Skalicky P, Klos D, Bebarova L, Neoral C, Ehrmann J, Zapletalova J, Svebisova H, Vrba R, Stasek M, Yogeswara T, Havlik R. Long-term survival after resections for pancreatic ductal adenocarcinoma. Single centre study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016;160:280-6. [PMID: 27029600 DOI: 10.5507/bp.2016.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
144 Landi F, Dopazo C, Sapisochin G, Beisani M, Blanco L, Caralt M, Balsells J, Charco R. Long-term results of pancreaticoduodenectomy with superior mesenteric and portal vein resection for ductal adenocarcinoma in the head of the pancreas. Cir Esp 2015;93:522-9. [PMID: 25981612 DOI: 10.1016/j.ciresp.2015.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
145 Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA, Donahue TR. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. J Gastrointest Surg 2016;20:1331-42. [PMID: 27114246 DOI: 10.1007/s11605-016-3149-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
146 Du C, da Silva A, Morales-Oyarvide V, Dias Costa A, Kozak MM, Dunne RF, Rubinson DA, Perez K, Masugi Y, Hamada T, Brais LK, Yuan C, Babic A, Ducar MD, Thorner AR, Aguirre A, Kulke MH, Ng K, Clancy TE, Findeis-Hosey JJ, Chang DT, Hornick JL, Fuchs CS, Ogino S, Koong AC, Hezel AF, Wolpin BM, Nowak JA. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2020;29:1586-95. [PMID: 32467349 DOI: 10.1158/1055-9965.EPI-19-1315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
147 Mejia JC, Dong M, Ojogho O. Pancreaticoduodenectomy in a patient with previous left ventricular assist device: a case report with specific emphasis on peri-operative logistics. J Surg Case Rep 2017;2017:rjx053. [PMID: 28458859 DOI: 10.1093/jscr/rjx053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
148 de Geus SW, Bliss LA, Eskander MF, Ng SC, Vahrmeijer AL, Mahadevan A, Kent TS, Moser AJ, Callery MP, Bonsing BA, Tseng JF. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care. J Gastrointest Surg 2016;20:85-92; discussion 92. [PMID: 26427374 DOI: 10.1007/s11605-015-2951-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
149 Reilley MJ, Shroff R, Varadhachary GR. Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer. Indian J Surg 2015;77:403-8. [PMID: 26722204 DOI: 10.1007/s12262-015-1361-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
150 Endo Y, Kitago M, Aiura K, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Nakano Y, Itano O, Fukada J, Masugi Y, Kitagawa Y. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. World J Surg Oncol. 2019;17:145. [PMID: 31420046 DOI: 10.1186/s12957-019-1687-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
151 Ilmer M, Schiergens TS, Renz BW, Schneider C, Sargut M, Waligora R, Weniger M, Hartwig W, Ceyhan GO, Friess H, Werner J, D'Haese JG. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Surg Oncol 2019;31:16-21. [PMID: 31473583 DOI: 10.1016/j.suronc.2019.08.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
152 Brieau B, Barret M, Rouquette A, Dréanic J, Brezault C, Regnard JF, Coriat R. Resection of Late Pulmonary Metastases from Pancreatic Adenocarcinoma: Is Surgery an Option? Cancer Invest 2015;33:522-5. [PMID: 26461032 DOI: 10.3109/07357907.2015.1080831] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
153 Lee SJ, Kim JH, Kim SY, Won HJ, Shin YM, Kim PN. Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma. Korean J Radiol 2020;21:316-24. [PMID: 32090524 DOI: 10.3348/kjr.2019.0647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
154 Hayman AV, Stocker SJ, Baker MS, Bentrem DJ, Prinz RA, Marsh RDW, Talamonti MS. CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2014;37:550-4. [DOI: 10.1097/coc.0b013e318280d5f0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
155 Kim HW, Lee J, Paik K, Kang J, Kim YH, Yoon Y, Han H, Kim J, Hwang J. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Surgery 2017;161:1579-87. [DOI: 10.1016/j.surg.2016.12.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
156 Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery 2018;267:936-45. [DOI: 10.1097/sla.0000000000002234] [Cited by in Crossref: 165] [Cited by in F6Publishing: 86] [Article Influence: 41.3] [Reference Citation Analysis]
157 Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011;15:1611-1617. [PMID: 21725701 DOI: 10.1007/s11605-011-1605-8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
158 Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, Caterino M, Ventriglia A, Orditura M, Conzo G, Molino C, Ciardiello F, Biglietto M, De Vita F. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Med Oncol 2019;36:83. [PMID: 31444639 DOI: 10.1007/s12032-019-1306-9] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
159 Binziad S, Salem AA, Amira G, Mourad F, Ibrahim AK, Manim TM. Impact of reconstruction methods and pathological factors on survival after pancreaticoduodenectomy. South Asian J Cancer 2013;2:160-8. [PMID: 24455609 DOI: 10.4103/2278-330X.114145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
160 Dal Molin M, Zhang M, de Wilde RF, Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B, Kinzler KW, Papadopoulos N, Hruban RH, Maitra A, Wood LD. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Clin Cancer Res 2015;21:1944-50. [PMID: 25623214 DOI: 10.1158/1078-0432.CCR-14-2600] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
161 Lin H, Ma Y, Wang JZ, Pan HY, Liu LX, Qiao HQ, Sun B, Jiang HC. Analysis of 300 consecutive cases of pancreatic adenocarcinoma in a single-center in China. Hepatobiliary Pancreat Dis Int 2016;15:189-97. [PMID: 27020636 DOI: 10.1016/s1499-3872(16)60066-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
162 Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19:2045-2053. [PMID: 22258816 DOI: 10.1245/s10434-011-2211-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
163 Falkenstern-Ge RF, Wohlleber M, Kimmich M, Huettl K, Friedel G, Ott G, Kohlhäufl M. Pulmonary adenocarcinoma occurring 5 years after resection of a primary pancreatic adenocarcinoma: a relevant differential diagnosis. Case Rep Oncol Med 2014;2014:841907. [PMID: 24716048 DOI: 10.1155/2014/841907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
164 Parmar AD, Vargas GM, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery. 2014;156:280-289. [PMID: 24851723 DOI: 10.1016/j.surg.2014.03.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
165 Chen KT, Devarajan K, Hoffman JP. Morbidity among long-term survivors after pancreatoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol 2015;22:1185-9. [PMID: 25384699 DOI: 10.1245/s10434-014-3969-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
166 Nofi CP, Maloney C, Kallis MP, Levy AT, Nealon WH, Weiss MJ, DePeralta DK. Rare, long-term complication after pancreatoduodenectomy-a case report of cecal volvulus. J Surg Case Rep 2021;2021:rjab202. [PMID: 34084448 DOI: 10.1093/jscr/rjab202] [Reference Citation Analysis]
167 Kersten C, Cvancarova M, Mjåland S, Mjåland O. Does in-house availability of multidisciplinary teams increase survival in upper gastrointestinal-cancer? World J Gastrointest Oncol 2013; 5(3): 60-67 [PMID: 23671732 DOI: 10.4251/wjgo.v5.i3.60] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
168 Zheng ZJ, Wang MJ, Tan CL, Chen YH, Ping J, Liu XB. Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study. Medicine (Baltimore) 2020;99:e19327. [PMID: 32080152 DOI: 10.1097/MD.0000000000019327] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Syed AR, Carleton NM, Horne Z, Dhawan A, Bedi G, Kochhar G, Morrissey S, Williams H, Atkinson D, Schiffman S, Monga D, Lupetin A, Kirichenko A, Mitre M, Dhawan M, Kulkarni A, Thakkar S. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy. J Gastrointest Cancer 2020;51:836-43. [PMID: 31605289 DOI: 10.1007/s12029-019-00303-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
171 Teixera SR, Kohan AA, Paspulati RM, Rong R, Herrmann KA. Potential Role of Positron Emission Tomography/Magnetic Resonance Imaging in Gastrointestinal and Abdominal Malignancies: Preliminary Experience. Seminars in Roentgenology 2014;49:321-33. [DOI: 10.1053/j.ro.2014.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
172 Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. [PMID: 27247221 DOI: 10.1200/jco.2016.67.5553] [Cited by in Crossref: 195] [Cited by in F6Publishing: 80] [Article Influence: 32.5] [Reference Citation Analysis]
173 Kaiho T, Suzuki H, Yamamoto T, Morimoto J, Sakairi Y, Wada H, Nakajima T, Yoshino I. Surgical outcomes of pulmonary metastasis from hepatopancreatobiliary carcinomas: a comparison with pulmonary metastasis from colorectal carcinomas. Surg Today 2019;49:762-8. [PMID: 30859309 DOI: 10.1007/s00595-019-01794-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Kagawa S, Takano S, Yoshitomi H, Kimura F, Satoh M, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Furukawa K, Matsushita K, Nomura F, Miyazaki M. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res 2012;178:758-67. [PMID: 22726648 DOI: 10.1016/j.jss.2012.05.065] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
175 Ng KYY, Chow EWX, Jiang B, Lim C, Goh BKP, Lee SY, Teo JY, Tan DMY, Cheow PC, Ooi LLPJ, Chow PKH, Lee JJX, Kam JH, Koh YX, Jeyaraj PR, Tan EK, Choo SP, Chan CY, Chung AYF, Tai D. Resected pancreatic adenocarcinoma: An Asian institution's experience. Cancer Rep (Hoboken) 2021;:e1393. [PMID: 33939335 DOI: 10.1002/cnr2.1393] [Reference Citation Analysis]
176 Loveday BP, Zilbert N, Serrano PE, Tomiyama K, Tremblay A, Fox AM, Segedi M, O'malley M, Borgida A, Bianco T, Creighton S, Dodd A, Fraser A, Moore M, Kim J, Cleary S, Moulton C, Greig P, Wei AC, Gallinger S, Dhani N, Mcgilvray ID. Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas. HPB 2019;21:643-52. [DOI: 10.1016/j.hpb.2018.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
177 Ricci C, Casadei R, Taffurelli G, Buscemi S, D'Ambra M, Monari F, Santini D, Campana D, Tomassetti P, Minni F. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. Pancreatology 2013;13:589-93. [PMID: 24280574 DOI: 10.1016/j.pan.2013.09.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
178 Uesato Y, Tamashiro K, Takatsuki M. Long-term survival after repeated resection for lung metastasis originating from pancreatic cancer: a case report. Surg Case Rep 2020;6:66. [PMID: 32266605 DOI: 10.1186/s40792-020-00832-x] [Reference Citation Analysis]
179 Berriochoa CA, Abdel-wahab M, Leyrer CM, Khorana A, Matthew Walsh R, Kumar AMS. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection: Neoadjuvant CRT for pancreatic cancer. Journal of Digestive Diseases 2017;18:642-9. [DOI: 10.1111/1751-2980.12551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
180 Miyasaka M, Noji T, Ohtaka K, Chiba R, Sato S, Shoji Y, Hase R, Ichimura T, Hirano S, Senmaru N. Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma. Clin J Gastroenterol 2018;11:53-61. [DOI: 10.1007/s12328-017-0781-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010;15:1205-1213. [PMID: 21045189 DOI: 10.1634/theoncologist.2010-0121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
182 Guerra F, Barucca V, Coletta D. Metastases or primary recurrence to the lung is related to improved survival of pancreatic cancer as compared to other sites of dissemination. Results of a systematic review with meta-analysis. Eur J Surg Oncol 2020;46:1789-94. [PMID: 32753117 DOI: 10.1016/j.ejso.2020.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Parker NH, Basen-Engquist K, Rubin ML, Li Y, Prakash L, Ngo-Huang A, Gorzelitz J, Ikoma N, Lee JE, Katz MHG. Factors Influencing Exercise Following Pancreatic Tumor Resection. Ann Surg Oncol 2021;28:2299-309. [PMID: 32886288 DOI: 10.1245/s10434-020-09062-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
184 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Reference Citation Analysis]
185 Neeman U, Lahat G, Goykhman Y, Geva R, Peles-Avraham S, Nachmany I, Nakache R, Klausner JM, Lubezky N. Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. Surgeon 2020;18:24-30. [PMID: 31466841 DOI: 10.1016/j.surge.2019.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
186 Wolfe AR, Prabhakar D, Yildiz VO, Cloyd JM, Dillhoff M, Abushahin L, Alexandra Diaz D, Miller ED, Chen W, Frankel WL, Noonan A, Williams TM. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med 2020;9:4711-23. [PMID: 32415696 DOI: 10.1002/cam4.3075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
187 Klaiber U, Hackert T. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment. Front Oncol. 2019;9:1501. [PMID: 31993372 DOI: 10.3389/fonc.2019.01501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
188 Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Kamata M, Ohe C, Sakaida N, Uemura Y, Kitade H, Tanigawa N, Inoue K, Matsui Y, Kwon AH. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg. 2012;16:784-792. [PMID: 22160780 DOI: 10.1007/s11605-011-1795-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
189 Ren W, Xourafas D, Ashley SW, Clancy TE. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection. Am Surg 2021;:31348211011129. [PMID: 33861651 DOI: 10.1177/00031348211011129] [Reference Citation Analysis]
190 Mullinax JE, Hernandez JM, Toomey P, Villadolid D, Bowers C, Cooper J, Rosemurgy AS. Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status. Am J Surg 2012;204:704-8. [PMID: 23140830 DOI: 10.1016/j.amjsurg.2012.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
191 Westgaard A, Clausen OPF, Gladhaug IP. Survival estimates after pancreatoduodenectomy skewed by non-standardized histopathology reports: STANDARDIZED HISTOPATHOLOGICAL EVALUATION. APMIS 2011;119:689-700. [DOI: 10.1111/j.1600-0463.2011.02783.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
192 Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295-301. [PMID: 25037971 DOI: 10.1245/s10434-014-3898-9] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 12.6] [Reference Citation Analysis]
193 Oppliger FA, Prakash LR, Newhook TE, Chiang YJ, Ikoma N, Maxwell JE, Kim MP, Vauthey JN, Lee JE, Katz MH, Tzeng CD. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Surg Oncol 2021;40:101673. [PMID: 34894620 DOI: 10.1016/j.suronc.2021.101673] [Reference Citation Analysis]
194 Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, Büchler MW, Hackert T. Meta-analysis of recurrence pattern after resection for pancreatic cancer. British Journal of Surgery 2019;106:1590-601. [DOI: 10.1002/bjs.11295] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
195 Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? Expert Review of Gastroenterology & Hepatology 2014;6:149-61. [DOI: 10.1586/egh.12.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Katz MH, Taylor TH, Al-Refaie WB, Hanna MH, Imagawa DK, Anton-Culver H, Zell JA. Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis. J Gastrointest Surg. 2011;15:165-174. [PMID: 21082275 DOI: 10.1007/s11605-010-1378-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
197 Katz MH, Crane CH, Varadhachary G. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol. 2014;24:105-112. [PMID: 24635867 DOI: 10.1016/j.semradonc.2013.11.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
198 Watanabe Y, Shinkawa T, Endo S, Abe Y, Nishihara K, Nakano T. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy. World J Surg 2018;42:2617-26. [DOI: 10.1007/s00268-018-4496-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
199 Zakem SJ, Mueller AC, Meguid C, Torphy RJ, Holt DE, Schefter T, Messersmith WA, McCarter MD, Del Chiaro M, Schulick RD, Goodman KA. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. HPB (Oxford) 2021;23:1072-83. [PMID: 33277184 DOI: 10.1016/j.hpb.2020.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Maksymov V, Hogan M, Khalifa MA. An anatomical-based mapping analysis of the pancreaticoduodenectomy retroperitoneal margin highlights the urgent need for standardized assessment. HPB (Oxford) 2013;15:218-23. [PMID: 23374362 DOI: 10.1111/j.1477-2574.2012.00561.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
201 Renz BW, Boeck S, Roeder F, Trumm C, Heinemann V, Werner J. Oligometastatic Disease in Pancreatic Cancer - How to Proceed? Visc Med 2017;33:36-41. [PMID: 28612015 DOI: 10.1159/000455027] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
202 Park HM, Park SJ, Shim JR, Lee EC, Lee SD, Han SS, Kim SH. Perioperative transfusion in pancreatoduodenectomy: The double-edged sword of pancreatic surgeons. Medicine (Baltimore) 2017;96:e9019. [PMID: 29245285 DOI: 10.1097/MD.0000000000009019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
203 Zhou Z, Cheng Y, Jiang Y, Liu S, Zhang M, Liu J, Zhao Q. Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. Int J Biol Sci. 2018;14:124-136. [PMID: 29483831 DOI: 10.7150/ijbs.22619] [Cited by in Crossref: 52] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
204 Hua J, Chen X, Chen Y, Lu B, Xu J, Wang W, Shi S, Yu X. Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). Hepatobiliary & Pancreatic Diseases International 2021;20:163-72. [DOI: 10.1016/j.hbpd.2020.12.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Oh SY, Edwards A, Mandelson MT, Lin B, Dorer R, Helton WS, Kozarek RA, Picozzi VJ. Rare long-term survivors of pancreatic adenocarcinoma without curative resection. World J Gastroenterol 2015; 21(48): 13574-13581 [PMID: 26730170 DOI: 10.3748/wjg.v21.i48.13574] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
206 Kasumova GG, Conway WC, Tseng JF. The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery. Ann Surg Oncol 2018;25:51-8. [DOI: 10.1245/s10434-016-5676-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
207 Vazzano J, Frankel WL, Wolfe AR, Williams TM, Chen W. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems. Hum Pathol 2021;109:1-11. [PMID: 33245985 DOI: 10.1016/j.humpath.2020.11.010] [Reference Citation Analysis]
208 Dusch N, Weiss C, Ströbel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2014;18:674-681. [PMID: 24241965 DOI: 10.1007/s11605-013-2408-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
209 Sabater L, García-granero A, Escrig-sos J, Gómez-mateo MDC, Sastre J, Ferrández A, Ortega J. Outcome Quality Standards in Pancreatic Oncologic Surgery. Ann Surg Oncol 2014;21:1138-46. [DOI: 10.1245/s10434-013-3451-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
210 Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol. 2011;174:1373-1381. [PMID: 22047824 DOI: 10.1093/aje/kwr267] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
211 Xu JZ, Wang WQ, Zhang WH, Xu HX, Gao HL, Zhang SR, Wu CT, Li S, Li H, Xu J, Yu XJ, Liu L. The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. J Cancer 2019;10:4123-31. [PMID: 31417657 DOI: 10.7150/jca.30883] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
212 Hussung S, Akhoundova D, Hipp J, Follo M, Klar RFU, Philipp U, Scherer F, von Bubnoff N, Duyster J, Boerries M, Wittel U, Fritsch RM. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer. BMC Cancer 2021;21:49. [PMID: 33430810 DOI: 10.1186/s12885-020-07736-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Li X, Wan Y, Lou J, Xu L, Shi A, Yang L, Fan Y, Yang J, Huang J, Wu Y, Niu T. Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography. EClinicalMedicine 2022;43:101215. [PMID: 34927034 DOI: 10.1016/j.eclinm.2021.101215] [Reference Citation Analysis]
214 Allaway RJ, Fischer DA, de Abreu FB, Gardner TB, Gordon SR, Barth RJ, Colacchio TA, Wood M, Kacsoh BZ, Bouley SJ, Cui J, Hamilton J, Choi JA, Lange JT, Peterson JD, Padmanabhan V, Tomlinson CR, Tsongalis GJ, Suriawinata AA, Greene CS, Sanchez Y, Smith KD. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget. 2016;7:17087-17102. [PMID: 26934555 DOI: 10.18632/oncotarget.7718] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
215 Desai V, Patel K, Sheth R, Barlass U, Chan YM, Sclamberg J, Bishehsari F. Pancreatic Fat Infiltration Is Associated with a Higher Risk of Pancreatic Ductal Adenocarcinoma. Visc Med 2020;36:220-6. [PMID: 32775353 DOI: 10.1159/000507457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
216 Christians KK, Lal A, Pappas S, Quebbeman E, Evans DB. Portal vein resection. Surg Clin North Am. 2010;90:309-322. [PMID: 20362788 DOI: 10.1016/j.suc.2009.12.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
217 Downs-Canner S, Zenati M, Boone BA, Varley PR, Steve J, Hogg ME, Zureikat A, Zeh HJ, Lee KK. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol 2015;112:80-5. [PMID: 26153355 DOI: 10.1002/jso.23943] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
218 Agrawal S. Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma. World J Clin Oncol 2017; 8(3): 255-260 [PMID: 28638795 DOI: 10.5306/wjco.v8.i3.255] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
219 van Roessel S, Kasumova GG, Tabatabaie O, Ng SC, van Rijssen LB, Verheij J, Najarian RM, van Gulik TM, Besselink MG, Busch OR, Tseng JF. Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center. Ann Surg Oncol 2018;25:1760-7. [PMID: 29651577 DOI: 10.1245/s10434-018-6467-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
220 Kang Y, Ling J, Suzuki R, Roife D, Chopin-Laly X, Truty MJ, Chatterjee D, Wang H, Thomas RM, Katz MH, Chiao PJ, Fleming JB. SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium. PLoS One 2014;9:e107948. [PMID: 25264609 DOI: 10.1371/journal.pone.0107948] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
221 Walston S, Salloum J, Grieco C, Wuthrick E, Diaz DA, Barney C, Manilchuk A, Schmidt C, Dillhoff M, Pawlik TM, Williams TM. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. Am J Clin Oncol 2018;41:1185-92. [PMID: 29727311 DOI: 10.1097/COC.0000000000000452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
222 Qin WX, Wu Y, Liu J, Qin BD, Liu K, Jiao XD, Wang Z, Chen WS, Zang YS. Primary squamous cell carcinoma of pancreas: a population-based study. Gland Surg 2021;10:1029-37. [PMID: 33842247 DOI: 10.21037/gs-20-317] [Reference Citation Analysis]
223 Vicente E, Quijano Y, Ielpo B, Duran H, Diaz E, Fabra I, Oliva C, Olivares S, Caruso R, Ferri V, Ceron R, Moreno A. Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma? Cir Esp 2014;92:305-15. [PMID: 24636076 DOI: 10.1016/j.ciresp.2013.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
224 Dugarova RS, Berelavichus SV, Kaldarov AR, Gorin DS. [Physical minimally invasive treatment of pancreatic insulinoma]. Khirurgiia (Mosk) 2018;:94-7. [PMID: 29697692 DOI: 10.17116/hirurgia2018494-97] [Reference Citation Analysis]
225 Jorgensen MS, Almerey T, Farres H, Oldenburg WA, Stauffer J, Hakaim AG. What to expect with major vascular reconstruction during Whipple procedures: a single institution experience and literature review. J Gastrointest Oncol 2019;10:95-102. [PMID: 30788164 DOI: 10.21037/jgo.2018.10.03] [Reference Citation Analysis]
226 Castleberry AW, White RR, De La Fuente SG, Clary BM, Blazer DG, McCann RL, Pappas TN, Tyler DS, Scarborough JE. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol. 2012;19:4068-4077. [PMID: 22932857 DOI: 10.1245/s10434-012-2585-y] [Cited by in Crossref: 94] [Cited by in F6Publishing: 81] [Article Influence: 9.4] [Reference Citation Analysis]
227 Akita H, Takahashi H, Eguchi H, Asukai K, Hasegawa S, Wada H, Iwagami Y, Yamada D, Tomimaru Y, Noda T, Gotoh K, Kobayashi S, Doki Y, Sakon M. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study. Ann Gastroenterol Surg 2021;5:381-9. [PMID: 34095729 DOI: 10.1002/ags3.12418] [Reference Citation Analysis]
228 Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014;18:146-55; discussion 155-6. [PMID: 24129825 DOI: 10.1007/s11605-013-2371-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
229 Tzeng CD, Cao HST, Lee JE, Pisters PWT, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey J, Aloia TA, Fleming JB, Katz MHG. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. J Gastrointest Surg 2014;18:16-25. [DOI: 10.1007/s11605-013-2412-1] [Cited by in Crossref: 121] [Cited by in F6Publishing: 107] [Article Influence: 13.4] [Reference Citation Analysis]
230 Wei K, Hackert T. Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:1971. [PMID: 33923884 DOI: 10.3390/cancers13081971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Low RRJ, Lim WW, Nguyen PM, Lee B, Christie M, Burgess AW, Gibbs P, Grimmond SM, Hollande F, Putoczki TL. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Cancers (Basel) 2021;13:4979. [PMID: 34638463 DOI: 10.3390/cancers13194979] [Reference Citation Analysis]
232 Masetti M, Zanini N, Martuzzi F, Fabbri C, Mastrangelo L, Landolfo G, Fornelli A, Burzi M, Vezzelli E, Jovine E. Analysis of prognostic factors in metastatic tumors of the pancreas: a single-center experience and review of the literature. Pancreas. 2010;39:135-143. [PMID: 19820422 DOI: 10.1097/mpa.0b013e3181bae9b3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
233 Jang JY, Kang JS, Han Y, Heo JS, Choi SH, Choi DW, Park SJ, Han SS, Yoon DS, Park JS, Yu HC, Kang KJ, Kim SG, Lee H, Kwon W, Yoon YS, Han HS, Kim SW. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci 2017;24:426-33. [PMID: 28514000 DOI: 10.1002/jhbp.465] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
234 Liu H, Xu Y, Liang K, Liu R. Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:1378. [PMID: 32974137 DOI: 10.3389/fonc.2020.01378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Davis JL, Pandalai PK, Ripley RT, Langan RC, Avital I. Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy. Pancreas. 2012;41:678-684. [PMID: 22695088 DOI: 10.1097/mpa.0b013e318249955a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
236 Rao B, Syed A, Singh S, Gulati A, Moussiade G, Garg M, Sharma M, Morrissey S, Williams H, Atkinson D, Schiffman S, Monga D, Lupetin A, Kirichenko A, Mitre M, Tang A, Dhawan M, Kulkarni A, Thakkar S. Performance of a Multidisciplinary Pancreatic Cancer Conference in Predicting and Managing Resectable Pancreatic Cancer. Pancreas 2019;48:80-4. [DOI: 10.1097/mpa.0000000000001209] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
237 Mathur A, Ross SB, Luberice K, Kurian T, Vice M, Toomey P, Rosemurgy AS. Margin Status Impacts Survival after Pancreaticoduodenectomy but Negative Margins Should Not be Pursued. The American Surgeon 2014;80:353-60. [DOI: 10.1177/000313481408000416] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 16.5] [Reference Citation Analysis]
238 Fisher AV, Abbott DE, Venkatesh M, Leverson GE, Campbell-flohr SA, Ronnekleiv-kelly SM, Greenberg CC, Winslow ER, Weber SM. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. Ann Surg Oncol 2018;25:2661-8. [DOI: 10.1245/s10434-018-6650-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
239 Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res. 2010;16:5712-5721. [PMID: 21138869 DOI: 10.1158/1078-0432.ccr-10-2055] [Cited by in Crossref: 118] [Cited by in F6Publishing: 46] [Article Influence: 10.7] [Reference Citation Analysis]
240 Kimura K, Amano R, Nakata B, Yamazoe S, Hirata K, Murata A, Miura K, Nishio K, Hirakawa T, Ohira M, Hirakawa K. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol 2014;12:360. [PMID: 25429841 DOI: 10.1186/1477-7819-12-360] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
241 Appel BL, Tolat P, Evans DB, Tsai S. Current Staging Systems for Pancreatic Cancer. The Cancer Journal 2012;18:539-49. [DOI: 10.1097/ppo.0b013e318278c5b5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
242 Umezaki N, Hashimoto D, Nakagawa S, Yamao T, Tsukamoto M, Kitano Y, Arima K, Yamamura K, Miyata T, Okabe H, Chikamoto A, Matsumura F, Baba H. Cystic gastric metastasis from pancreatic cancer.Surg Case Rep. 2018;4:31. [PMID: 29633044 DOI: 10.1186/s40792-018-0443-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
243 Armstrong L, Arrington A, Han J, Gavrikova T, Brown E, Yamamoto M, Vickers SM, Davydova J. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. Am J Surg 2012;204:741-50. [PMID: 22748294 DOI: 10.1016/j.amjsurg.2012.02.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
244 Christians KK, Pilgrim CH, Tsai S, Ritch P, George B, Erickson B, Tolat P, Evans DB. Arterial resection at the time of pancreatectomy for cancer. Surgery. 2014;155:919-926. [PMID: 24787115 DOI: 10.1016/j.surg.2014.01.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
245 Chen JW, Bhandari M, Astill DS, Wilson TG, Kow L, Brooke-Smith M, Toouli J, Padbury RT. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford). 2010;12:101-108. [PMID: 20495653 DOI: 10.1111/j.1477-2574.2009.00140.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
246 Busquets J, Fabregat J, Verdaguer H, Laquente B, Pelaez N, Secanella L, Leiva D, Serrano T, Cambray M, Lopez-urdiales R, Ramos E. Initial Experience in the Treatment of “Borderline Resectable” Pancreatic Adenocarcinoma. Cirugía Española (English Edition) 2017;95:447-56. [DOI: 10.1016/j.cireng.2017.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
247 Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015;22 Suppl 3:S1221-S1228. [PMID: 26350371 DOI: 10.1245/s10434-015-4854-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
248 Jouffret L, Turrini O, Ewald J, Moutardier V, Iovanna JL, Delpero JR. Long-term survivors after pancreatectomy for cancer: the TNM classification is outdated. ANZ J Surg 2015;85:860-4. [PMID: 26331377 DOI: 10.1111/ans.13277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
249 Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466-473. [PMID: 21878232 DOI: 10.1016/j.surg.2011.07.006] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 12.5] [Reference Citation Analysis]
250 Walsh GL. Pancreatic cancer patients and thoracic surgeons: Could/should their clinic templates ever overlap? J Thorac Cardiovasc Surg 2016;152:83-4. [PMID: 27103131 DOI: 10.1016/j.jtcvs.2016.03.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
251 Chen SC, Shyr YM, Chou SC, Wang SE. The role of lymph nodes in predicting the prognosis of ampullary carcinoma after curative resection. World J Surg Oncol 2015;13:224. [PMID: 26205252 DOI: 10.1186/s12957-015-0643-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
252 Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC. Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. Ann Surg Oncol 2013;20:1230-9. [PMID: 23064778 DOI: 10.1245/s10434-012-2648-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
253 Singh KJ, Galagali A, Menon G. Carcinoma pancreas. Med J Armed Forces India 2012;68:280-3. [PMID: 24532888 DOI: 10.1016/j.mjafi.2012.04.013] [Reference Citation Analysis]
254 Sutton TL, Grossberg A, Ey F, O'Reilly EM, Sheppard BC. Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both? Cancer Biol Ther 2021;:1-5. [PMID: 34696697 DOI: 10.1080/15384047.2021.1991739] [Reference Citation Analysis]
255 Miccio JA, Talcott WJ, Patel T, Park HS, Cecchini M, Salem RR, Khan SA, Stein S, Kortmansky JS, Lacy J, Narang A, Herman J, Jabbour SK, Hallemeier CL, Johung K, Jethwa KR. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clin Transl Radiat Oncol 2021;27:15-23. [PMID: 33392398 DOI: 10.1016/j.ctro.2020.12.003] [Reference Citation Analysis]
256 John BJ, Naik P, Ironside A, Davidson BR, Fusai G, Gillmore R, Watkins J, Rahman SH. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford) 2013;15:674-80. [PMID: 23458477 DOI: 10.1111/hpb.12019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
257 Parker NH, Gorzelitz J, Ngo-Huang A, Caan BJ, Prakash L, Garg N, Petzel MQB, Schadler K, Basen-Engquist K, Katz MHG. The Role of Home-Based Exercise in Maintaining Skeletal Muscle During Preoperative Pancreatic Cancer Treatment. Integr Cancer Ther 2021;20:1534735420986615. [PMID: 33870744 DOI: 10.1177/1534735420986615] [Reference Citation Analysis]
258 Metildi CA, Kaushal S, Lee C, Hardamon CR, Snyder CS, Luiken GA, Talamini MA, Hoffman RM, Bouvet M. An LED light source and novel fluorophore combinations improve fluorescence laparoscopic detection of metastatic pancreatic cancer in orthotopic mouse models. J Am Coll Surg 2012;214:997-1007.e2. [PMID: 22542065 DOI: 10.1016/j.jamcollsurg.2012.02.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
259 Cellini F, Arcelli A, Simoni N, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers (Basel). 2020;12. [PMID: 32610592 DOI: 10.3390/cancers12071729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
260 Leong SP, Nakakura EK, Pollock R, Choti MA, Morton DL, Henner WD, Lal A, Pillai R, Clark OH, Cady B. Unique patterns of metastases in common and rare types of malignancy. J Surg Oncol 2011;103:607-14. [PMID: 21480255 DOI: 10.1002/jso.21841] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
261 Schwarz L, Katz MH. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:727-40. [PMID: 26226907 DOI: 10.1016/j.hoc.2015.04.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
262 Nayar P, Chandak A, Gupta N, Yu F, Qiu F, Ganti AK, Are C. Postoperative mortality following multi-modality therapy for pancreatic cancer: Analysis of the SEER-Medicare data. J Surg Oncol 2017;115:158-63. [PMID: 28133817 DOI: 10.1002/jso.24472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
263 Kim JR, Kim H, Kwon W, Jang JY, Kim SW. Pattern of local recurrence after curative resection in pancreatic ductal adenocarcinoma according to the initial location of the tumor. J Hepatobiliary Pancreat Sci 2021;28:105-14. [PMID: 33084211 DOI: 10.1002/jhbp.854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
264 Mathy RM, Fritz F, Mayer P, Klauss M, Grenacher L, Stiller W, Kauczor HU, Skornitzke S. Iodine concentration and tissue attenuation in dual-energy contrast-enhanced CT as a potential quantitative parameter in early detection of local pancreatic carcinoma recurrence after surgical resection. Eur J Radiol 2021;143:109944. [PMID: 34482176 DOI: 10.1016/j.ejrad.2021.109944] [Reference Citation Analysis]
265 Gu X, Zhou R, Li C, Liu R, Zhao Z, Gao Y, Xu Y. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma. BMC Cancer 2019;19:456. [PMID: 31092213 DOI: 10.1186/s12885-019-5691-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
266 Ren H, Wu CR, Aimaiti S, Wang CF. Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma. Oncol Lett 2020;19:4093-105. [PMID: 32382348 DOI: 10.3892/ol.2020.11495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Vanbrugghe C, Birnbaum DJ, Boucekine M, Ewald J, Marchese U, Guilbaud T, Berdah SV, Moutardier V. Prospective study on predictability of complications by pancreatic surgeons. Langenbecks Arch Surg 2020;405:155-63. [PMID: 32285190 DOI: 10.1007/s00423-020-01866-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
268 Maharaj AD, Evans SM, Zalcberg JR, Ioannou LJ, Graco M, Croagh D, Pilgrim CHC, Dodson T, Goldstein D, Philip J, Kench JG, Merrett ND, Neale RE, White K, Evans P, Leong T, Green SE. Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework. BMJ Qual Saf 2021;30:792-803. [DOI: 10.1136/bmjqs-2020-011793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
269 Herman JM, Jabbour SK, Lin SH, Deek MP, Hsu CC, Fishman EK, Kim S, Cameron JL, Chekmareva M, Laheru DA, Narang AK, Pawlik TM, Hruban RH, Wolfgang CL, Iacobuzio-Donahue CA. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 2018;47:208-12. [PMID: 29329157 DOI: 10.1097/MPA.0000000000000985] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
270 Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10:16425. [PMID: 33009477 DOI: 10.1038/s41598-020-73525-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
271 Mise Y, Vauthey JN, Zimmitti G, Parker NH, Conrad C, Aloia TA, Lee JE, Fleming JB, Katz MH. Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality. Ann Surg 2015;262:1071-8. [PMID: 25590497 DOI: 10.1097/SLA.0000000000001048] [Cited by in Crossref: 81] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
272 Castellanos JA, Merchant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol 2014;21:747-51. [PMID: 24092447 DOI: 10.1245/s10434-013-3289-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
273 Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol. 2011;18:2116-2125. [PMID: 21442345 DOI: 10.1245/s10434-011-1675-6] [Cited by in Crossref: 223] [Cited by in F6Publishing: 202] [Article Influence: 20.3] [Reference Citation Analysis]
274 Lounis L, Aurran-schleinitz T, Turrini O, Delpero J, Bréjard V. Psychological Outcomes and Quality of Life in Relation to Pancreatectomy: A Systematic Review. Pancreas 2019;48:471-9. [DOI: 10.1097/mpa.0000000000001279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
275 Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A, Sperti C. Surgery for Recurrent Pancreatic Cancer: Is It Effective? Cancers (Basel) 2019;11:E991. [PMID: 31315222 DOI: 10.3390/cancers11070991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
276 Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168-1175. [PMID: 25352267 DOI: 10.1245/s10434-014-4192-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 8.5] [Reference Citation Analysis]
277 Cannon RM, LeGrand R, Chagpar RB, Ahmad SA, McClaine R, Kim HJ, Rupp C, Cho CS, Brinkman A, Weber S. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford). 2012;14:228-235. [PMID: 22404260 DOI: 10.1111/j.1477-2574.2011.00432.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
278 Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol 2017;28:741-7. [PMID: 28104621 DOI: 10.1093/annonc/mdx004] [Cited by in Crossref: 188] [Cited by in F6Publishing: 192] [Article Influence: 37.6] [Reference Citation Analysis]
279 Hackert T. Surgery for Pancreatic Cancer after neoadjuvant treatment. Ann Gastroenterol Surg 2018;2:413-8. [PMID: 30460344 DOI: 10.1002/ags3.12203] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
280 Le AT, Tzeng CW. Does finding early recurrence improve outcomes, and at what cost? J Surg Oncol 2016;114:329-35. [PMID: 27393742 DOI: 10.1002/jso.24370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
281 Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol 2015;141:1653-60. [PMID: 25792009 DOI: 10.1007/s00432-015-1953-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
282 Moore MD, Postma E, Gray KD, Ullmann TM, Hurley JR, Goldsmith S, Sobel VR, Schulman A, Scognamiglio T, Christos PJ, Hassett E, Luick J, Whitehall D, Zarnegar R, Fahey TJ 3rd. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma. World J Surg 2018;42:343-9. [PMID: 29058064 DOI: 10.1007/s00268-017-4308-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
283 Schwarz C, Fitschek F, Primavesi F, Stättner S, Margonis GA, Weiss MA, Stavrou GA, Oldhafer KJ, Kornprat P, Wundsam H, Fischer I, Längle F, Függer R, Hauer A, Klug R, Kieler M, Prager G, Schindl M, Stremitzer S, Bodingbauer M, Sahora K, Kaczirek K. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol 2020;35:169-73. [PMID: 32889249 DOI: 10.1016/j.suronc.2020.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
284 Dang C, Wang M, Zhu F, Qin T, Qin R. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with pancreatic cancer undergoing radical surgery. Asian J Surg 2021:S1015-9584(21)00513-3. [PMID: 34493426 DOI: 10.1016/j.asjsur.2021.08.011] [Reference Citation Analysis]
285 Luu AM, Braumann C, Belyaev O, Janot-Matuschek M, Rudolf H, Praktiknjo M, Uhl W. Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. Hepatobiliary Pancreat Dis Int 2021;20:271-8. [PMID: 33349608 DOI: 10.1016/j.hbpd.2020.12.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Wei HT, Chen GY, Li P. Mediastinum metastasis in a post-surgical pancreatic cancer patient successfully confirmed with endoscopic ultrasonography. World J Emerg Med 2021;12:244-6. [PMID: 34141045 DOI: 10.5847/wjem.j.1920-8642.2021.03.017] [Reference Citation Analysis]
287 Kim HW, Lee JC, Lee J, Kim JW, Kim J, Hwang JH. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. PLoS One 2017;12:e0173960. [PMID: 28301556 DOI: 10.1371/journal.pone.0173960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
288 Kooby DA, Hawkins WG, Schmidt CM, Weber SM, Bentrem DJ, Gillespie TW, Sellers JB, Merchant NB, Scoggins CR, Martin RC. A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg. 2010;210:779-785, 786-787. [PMID: 20421049 DOI: 10.1016/j.jamcollsurg.2009.12.033] [Cited by in Crossref: 217] [Cited by in F6Publishing: 204] [Article Influence: 18.1] [Reference Citation Analysis]
289 Daamen LA, Groot VP, Intven MPW, Besselink MG, Busch OR, Koerkamp BG, Mohammad NH, Hermans JJ, van Laarhoven HWM, Nuyttens JJ, Wilmink JW, van Santvoort HC, Molenaar IQ, Stommel MWJ; Dutch Pancreatic Cancer Group. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol 2019;45:1770-7. [PMID: 31204168 DOI: 10.1016/j.ejso.2019.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
290 Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012;215:41-51; discussion 51-52. [PMID: 22608401 DOI: 10.1016/j.jamcollsurg.2012.03.024.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Balaj C, Ayav A, Oliver A, Jausset F, Sellal C, Claudon M, Laurent V. CT imaging of early local recurrence of pancreatic adenocarcinoma following pancreaticoduodenectomy. Abdom Radiol 2016;41:273-82. [DOI: 10.1007/s00261-015-0564-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
292 Tian XD, Yang YM. A new nomogram for predicting lymph node positivity in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2021;20:103-4. [PMID: 33546987 DOI: 10.1016/j.hbpd.2020.12.022] [Reference Citation Analysis]
293 Kang CM, Choi JY, Seong JS, Song SY, Lee WJ, Kim MJ, Chung JB. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer. Pancreas 2012;41:467-73. [PMID: 22158068 DOI: 10.1097/MPA.0b013e31822a68bc] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
294 Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol 2021;11:651119. [PMID: 34046346 DOI: 10.3389/fonc.2021.651119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Shin J, Kim SH, Suh SY, Cheng SY, Chen PJ, Yamaguchi T, Morita T, Tsuneto S, Mori M; EASED investigators. Physical and psychological symptoms and signs in dying digestive tract cancer patients: the East Asian collaborative cross-cultural Study to Elucidate the Dying process (EASED). Support Care Cancer 2021;29:3603-12. [PMID: 33170402 DOI: 10.1007/s00520-020-05866-3] [Reference Citation Analysis]
296 Mashiko T, Nakano A, Masuoka Y, Yamamoto S, Ozawa S, Nakagohri T. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Surg 2021;21:237. [PMID: 33952223 DOI: 10.1186/s12893-021-01236-w] [Reference Citation Analysis]
297 Kawai M, Tani M, Hirono S, Okada K, Miyazawa M, Yamaue H. Pylorus-Resecting Pancreaticoduodenectomy Offers Long-Term Outcomes Similar to Those of Pylorus-Preserving Pancreaticoduodenectomy: Results of a Prospective Study. World J Surg 2014;38:1476-83. [DOI: 10.1007/s00268-013-2420-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
298 Best LM, Rawji V, Pereira SP, Davidson BR, Gurusamy KS. Imaging modalities for characterising focal pancreatic lesions. Cochrane Database Syst Rev 2017;4:CD010213. [PMID: 28415140 DOI: 10.1002/14651858.CD010213.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
299 Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM, Swartz MJ, Winter JM, Robinson R, Edil BH, Narang AK, Choti MA, Hruban RH, Cameron JL, Schulick RD, Herman JM. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg 2012;16:753-61. [PMID: 22311282 DOI: 10.1007/s11605-011-1811-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
300 Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas 2018;47:958-66. [PMID: 30074526 DOI: 10.1097/MPA.0000000000001133] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
301 Xu X, Lv Y, Zhang L, Xin B, Li JA, Wang D, Kuang T, Lou W, Jin D. Application of a novel embeddedness-like pancreaticojejunostomy anastomosis technique used in pancreaticoduodenectomy. Oncol Lett 2018;15:8067-71. [PMID: 29849808 DOI: 10.3892/ol.2018.8334] [Reference Citation Analysis]
302 Yoshikawa K, Mitsunaga S, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, Aizawa M, Ochiai A. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci 2012;103:2012-20. [PMID: 22931216 DOI: 10.1111/j.1349-7006.2012.02411.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 8.8] [Reference Citation Analysis]
303 Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16:430-438. [PMID: 23991810 DOI: 10.1111/hpb.12154] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 12.2] [Reference Citation Analysis]
304 Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer 2016;122:2671-9. [PMID: 27243381 DOI: 10.1002/cncr.30117] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
305 Armstrong L, Davydova J, Brown E, Han J, Yamamoto M, Vickers SM. Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy. Surgery. 2012;152:114-122. [PMID: 22503318 DOI: 10.1016/j.surg.2012.02.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
306 Backlund DC, Berlin JD, Parikh AA. Update on adjuvant trials for pancreatic cancer. Surg Oncol Clin N Am 2010;19:391-409. [PMID: 20159521 DOI: 10.1016/j.soc.2009.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
307 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012;148:362-75. [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060] [Cited by in Crossref: 278] [Cited by in F6Publishing: 247] [Article Influence: 27.8] [Reference Citation Analysis]
308 Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12:427-433. [PMID: 20662794 DOI: 10.1111/j.1477-2574.2010.00198.x] [Cited by in Crossref: 136] [Cited by in F6Publishing: 110] [Article Influence: 12.4] [Reference Citation Analysis]
309 Zhong Y, Macgregor-Das A, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT, Javier BM, Cope L, Leach SD, Hingorani SR, Iacobuzio-Donahue CA. Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 2017;23:1607-20. [PMID: 27637888 DOI: 10.1158/1078-0432.CCR-15-1615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
310 Merchant NB, Parikh AA, Liu EH. Adjuvant chemoradiation therapy for pancreas cancer: who really benefits? Adv Surg 2010;44:149-64. [PMID: 20919520 DOI: 10.1016/j.yasu.2010.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
311 Overbeek KA, Cahen DL, Canto MI, Bruno MJ. Surveillance for neoplasia in the pancreas. Best Pract Res Clin Gastroenterol 2016;30:971-86. [PMID: 27938791 DOI: 10.1016/j.bpg.2016.10.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
312 Denbo JW, Fleming JB. Definition and Management of Borderline Resectable Pancreatic Cancer. Surg Clin North Am 2016;96:1337-50. [PMID: 27865281 DOI: 10.1016/j.suc.2016.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]